Health Care Plans' Stocks Under Review -- CVS Health, Express Scripts Holding, UnitedHealth Group, and Centene

Jul 22, 2016, 07:30 ET from Chelmsford Park SA

NEW YORK, July 22, 2016 /PRNewswire/ --

The Health Care Plans industry continues to capitalize on new opportunities while addressing affordability issues. In order to provide better consumer experience, companies are constantly improving their business models and technologies. Today, takes a look at four companies within this industry: CVS Health Corp. (NYSE: CVS), Express Scripts Holding Co. (NASDAQ: ESRX), UnitedHealth Group Inc. (NYSE: UNH), and Centene Corp. (NYSE: CNC). Learn more about these stocks by accessing their free notes at:

CVS Health  

At the close on Thursday, shares in Woonsocket, Rhode Island headquartered CVS Health Corp. saw a slight decline of 0.05%, ending the day at $96.95. The stock recorded a trading volume of 3.06 million shares. The Company's shares have advanced 4.47% in the last one month and 0.46% on an YTD basis. The stock is trading above its 50-day moving average by 0.11%. Moreover, shares of CVS Health, which together with its subsidiaries, provide integrated pharmacy health care services, have a Relative Strength Index (RSI) of 57.64.

On June 23rd, 2016, research firm Mizuho reiterated its 'Buy' rating with a decrease of the target price to $108 a share from $117 a share for the Company's stock.

On July 07th, 2016, a new study from the CVS Health Research Institute found that medication reconciliation programs, in which pharmacists review patients' medication regimens and provide adherence counseling during the patient's transition from hospital to home, reduced risk of hospital readmission by 50% and helped avoid unnecessary health care costs. The research, published in the July 2016 issue of Health Affairs, is the first to evaluate the impact of an insurer-supported medication reconciliation program on clinical outcomes and health care spending. Register now and access free notes on CVS at:

Express Scripts Holding  

Shares in St. Louis, Missouri headquartered Express Scripts Holding Co. ended the day 0.75% lower at $78.59 and with a total volume of 3.31 million shares traded. In the last month and the previous three months, the stock has gained 5.14% and 7.17%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 4.05% and 1.91%, respectively. Furthermore, shares of Express Scripts Holding, which operates as a pharmacy benefit management (PBM) company in the U.S., Canada, and Europe, have an RSI of 61.25. The complimentary notes on ESRX can be accessed at:

UnitedHealth Group  

On Thursday, shares in Minnetonka, Minnesota-based UnitedHealth Group Inc. finished 0.10% lower at $142.87. A total volume of 3.50 million shares was traded, which was above their three months average volume of 3.27 million shares. The stock has advanced 3.39% in the last one month, 7.94% over the previous three months, and 22.50% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 4.52% and 15.86%, respectively. Additionally, shares of UnitedHealth Group, which operates as a diversified health and well-being company in the U.S., have an RSI of 65.23.

On July 19th, 2016, as reported by Bloomberg, UnitedHealth Group second-quarter profit beat analysts' estimates driven by growth at its Optum technology and consulting unit. Earnings were $1.96 a share, excluding some items, as compared to the $1.89 average estimate of 21 analysts surveyed by Bloomberg. The company also raised the lower end of its 2016 earnings forecast range by 5 cents. UnitedHealth Group now expects earnings of $7.80 to $7.95 a share, excluding some items, up from $7.75 to $7.95. Analysts anticipate $7.89, on average.

On July 20th, 2016, research firm RBC Capital Markets reiterated its 'Outperform' rating with an increase of the target price to $165 a share from $157 a share for the Company's stock. Register for free on and access the latest notes on UNH at:


St. Louis, Missouri headquartered Centene Corp.'s stock recorded a trading volume of 1.36 million shares at the end of yesterday's session and closed the day at $73.00, gaining 0.76%. The stock has advanced 5.63% in the last one month, 20.66% over the previous three months, and 10.93% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 10.86% and 18.99%, respectively. Additionally, shares of Centene have an RSI at 70.65.

On June 29th, 2016, research firm Morgan Stanley upgraded the Company's stock ratings from 'Equal-Weight' to 'Overweight'.

On July 21st, 2016, Centene Corp. announced that the Department of Defense intends to award its wholly-owned subsidiary, Health Net Federal Services, LLC, the TRICARE West Region Contract. The TRICARE West Region contract includes a base period with additional five one-year option periods. The company expects the start of healthcare delivery to commence sometime mid-year of 2017. The TRICARE West Region Contract will be comprised of serving 2.9 million of eligible beneficiaries in 19 states and regions.  Get free access to your notes on CNC at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA